Medtronic (MDT) announced the U.S. Food and Drug Administration granted Breakthrough Device Designation for the Sphere-9 catheter for the treatment of VT, providing an expedited regulatory pathway for the technology.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target lowered to $95 from $108 at Jefferies
- Medtronic: Portfolio Streamlining and Diabetes Spin-Off Benefits Offset by Lower Growth Outlook and Valuation Compression, Justifying Hold Rating
- Medtronic price target lowered to $90 from $104 at UBS
- Medtronic price target lowered to $95 from $103 at Truist
- 3 Dividend Aristocrat Stocks Set to Reign With 15%+ Returns, 04/14/2026